The trial is currently active across Europe, utilizing a randomized, double-blind, placebo-controlled framework to assess the efficacy and safety of two different dose levels of the drug. By targeting the mPGES-1 enzyme—which drives the production of the proinflammatory mediator prostaglandin E2—researchers hope to offer a novel alternative to existing hormonal therapies and surgical interventions. If successful, the study will provide essential data to guide the development of a future Phase 3 program.

Eva Johnsson, Chief Medical Officer at Gesynta Pharma, noted that the recruitment pace has exceeded initial internal projections. The company remains focused on finalizing enrollment to maintain this momentum, with top-line results expected to be released in 2027. The drug candidate, which demonstrated a reduction in lesion burden during preclinical models, is being tested on women aged 18 to 45 over a period of four menstrual cycles.